A protein has been identified as a potential therapeutic target for leishmaniasis vaccines

(Universidad Complutense de Madrid) According to the World Health Organisation (WHO), leishmaniasis causes between 20,000 and 30,000 deaths a year, and there is currently no vaccine for humans. A research team led by the Complutense University of Madrid has described the mechanism by which the Leishmania parasite avoids detection: through the SHP-1 protein, which is responsible for basic cellular functions. The finding positions this protein as a potential therapeutic target for the development of vaccines against the disease.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Biomed Pharmacother. 2021 Jul 20;141:111920. doi: 10.1016/j.biopha.2021.111920. Online ahead of print.ABSTRACTThe study of tropical diseases like leishmaniasis, a parasitic disease, has not received much attention even though it is the second-largest infectious disease after malaria. As per the WHO report, a total of 0.7-1.0 million new leishmaniasis cases, which are spread by 23 Leishmania species in more than 98 countries, are estimated with an alarming 26,000-65,000 death toll every year. Lack of potential vaccines along with the cost and toxicity of amphotericin B (AmB), the most common drug for the treatment of leishm...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Source Type: research
In this study, Th1/Th2 cytokine profiles of CL patients were evaluated against live versus killed Leishmania major.METHODS: In this study peripheral blood mononuclear cells (PBMC) of the volunteers with active CL lesion (CL), history of CL (HCL) and healthy volunteers were cultured and stimulated with live or killed Leishmania major, the supernatants were collected and levels of IFN-γ, IL-5 and IL-10 were titrated using ELISA method.RESULTS: The results showed that IFN-γ levels in CL patients (p
Source: Iranian Journal of Arthropod-Borne Diseases - Category: Infectious Diseases Authors: Source Type: research
by Rinez Thapa, Subhasish Mondal, Joakim Riikonen, Jimi Rantanen, Simo N äkki, Tuomo Nissinen, Ale Närvänen, Vesa-Pekka Lehto Visceral leishmaniasis is a vector-borne protozoan infection that is fatal if untreated. There is no vaccination against the disease, and the current chemotherapeutic agents are ineffective due to increased resistance and severe side effects. Buparvaquone is a potential drug against the leishmania ses, but it is highly hydrophobic resulting in poor bioavailability and low therapeutic efficacy. Herein, we loaded the drug into silicon nanoparticles produced from barley husk, which is a...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
This study aims to determine the production of recombinant filamentous protein carried subunits of the surface protein ofToxoplasma gondii for vaccination purposes.Leishmania codon-optimised SAG1 was cloned as a fusion construct into pLEXSY-ble2.1 plasmid and introduced intoLeishmania tarentolae to generate recombinant cell lines expressing a filamentous fusion protein called SAP2SAG1. PCR confirmed the correct integration into the small ribosomal subunit RNA gene locus ofLeishmania tarentolae. Immunofluorescences and Immunoblot analyses were used to detect the fusion protein in the sediment of culture supernatants of reco...
Source: Journal of Parasitic Diseases - Category: Parasitology Source Type: research
CONCLUSION: Alterations in the expression profiles of genes common to L. major and L. infantum species may cause differences in the virulence, pathogenesis, clinical features and treatment modality between these parasite species. In addition, evaluation of gene profiles is important in the selection of species-specific or common targets for vaccine and drug studies.PMID:34103283 | DOI:10.4274/tpd.galenos.2021.66375
Source: Turkish Society for Parasitology - Category: Parasitology Authors: Source Type: research
More News: HIV-Leishmania Co-infection | International Medicine & Public Health | Parasitic Diseases | Parasitology | Vaccines | WHO